NCT03646110

Brief Summary

Minimally invasive esophagectomy (MIE) has been gradually adopted as a feasible and effective treatment option for esophageal cancer. Previously the investigators have published the adoption of single-incision approach both in the thoracoscopic and laparoscopic phases in MIE (SIMIE).The preliminary clinical results showed that SIMIE can provide an equivalent perioperative outcome whereas reduced the wound pain on the days 7 after surgery as compared to MIE performed with multi-incision (MIMIE). The goal of the current study was to conduct a prospective randomized trial to compare the perioperative outcome and survival of SIMIE and MIMIE.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 17, 2018

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

August 20, 2018

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 24, 2018

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 26, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 26, 2021

Completed
Last Updated

November 5, 2020

Status Verified

November 1, 2020

Enrollment Period

2.9 years

First QC Date

August 20, 2018

Last Update Submit

November 3, 2020

Conditions

Keywords

esophageal cancerMinimally invasive esophagectomy (MIE)single-incision Minimally invasive esophagectomy (SIMIE)

Outcome Measures

Primary Outcomes (1)

  • Overall survival rate

    Overall survival rate of the participants after surgery

    60 months

Secondary Outcomes (5)

  • Pain score as assessed by the face rating scale

    1,7,14,28 days

  • Ratio of ambulation

    post-operative day 2 (POD2)

  • Postoperative force vital capacity

    1 and 3 months

  • Post operative forced expiratory volume in one second

    1 and 3 months

  • Postoperative pulmonary complication

    1 month

Study Arms (2)

single-incision MIE

EXPERIMENTAL

Esophageal cancer patients received single-incision Minimally invasive esophagectomy

Procedure: Minimally invasive esophagectomy

multi-incision MIE

ACTIVE COMPARATOR

Esophageal cancer patients received multi-incision Minimally invasive esophagectomy

Procedure: Minimally invasive esophagectomy

Interventions

Minimally invasive esophagectomy is a surgical procedure for esophageal resection

multi-incision MIEsingle-incision MIE

Eligibility Criteria

Age35 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with a diagnosis of esophageal cancer
  • Age between 35 to 75 years old
  • Resectable tumor as evaluation by preoperative imaging studies.

You may not qualify if:

  • Previous surgery in the chest or abdomen.
  • Receiving definitive chemoradiation (5500 cGy or more).
  • Tumor invasion to the trachea, spine or aorta.
  • Liver cirrhosis with esophageal varices or liver cirrhosis refractory to medical treatment, Child C classification.
  • Previous history of cerebral vascular attack.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jang-Ming Lee

Taipei, Zhongzheng Dist., 100, Taiwan

RECRUITING

Related Links

MeSH Terms

Conditions

Esophageal Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsDigestive System DiseasesEsophageal DiseasesGastrointestinal Diseases

Central Study Contacts

Jang-Ming Lee, MD PhD

CONTACT

Pei-Wen Yang, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 20, 2018

First Posted

August 24, 2018

Study Start

August 17, 2018

Primary Completion

July 26, 2021

Study Completion

July 26, 2021

Last Updated

November 5, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations